Avastin Trial Enrollment To Resume With Heightened Cardiac Monitoring
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche/Genentech's AVANT study of bevacizumab showed no increase in cardiac adverse events, according to an independent data safety monitoring board.
You may also be interested in...
Avastin User Fee Date (correction)
Genentech's Avastin (bevacizumab) has a user fee date in June under a priority review for patients with previously treated metastatic colorectal cancer. "The Pink Sheet" DAILY had reported an incorrect user fee date for the new indication in a May 23 1article
Avastin User Fee Date (correction)
Genentech's Avastin (bevacizumab) has a user fee date in June under a priority review for patients with previously treated metastatic colorectal cancer. "The Pink Sheet" DAILY had reported an incorrect user fee date for the new indication in a May 23 1article
Genentech Halts Enrollment In Avastin Early-Stage Colon Cancer Trial
The firm reports a higher rate of non-colon cancer related deaths in the AVANT trial for adjuvant use of bevacizumab.